Figure 5.

In-vivo therapeutic activity of Ac-PLP-cIBR-NH₂-1 in reversing experimental autoimmune encephalomyelitis (EAE) in the mouse model. The mice were immunized with proteolipid protein (PLP)_139–151/complete Freund's adjuvant (CFA) followed by intravenous treatments of Ac-PLP-cIBR-NH₂-1 (50 nmol/injection/day) up to a maximum of three injections starting on the day of disease onset. (a) Clinical EAE disease score. (b) Change in body weight. Results are expressed as the mean ± standard error of the mean (n = 10). There are significant differences (P < 0·001) in EAE clinical scores and loss of body weight between Ac-PLP-cIBR-NH₂-1- and phosphate-buffered saline (PBS)-treated mice.